Cooperate with East China medicine MSD to complete the layout of "three in one"

April 17, 2013 source: 21st century economic report on April 16, Hangzhou Xiasha new plant invested 120 million US dollars by MSD, a foreign pharmaceutical company, was officially put into operation, with East China Pharmaceutical Group holding 15% of the shares This action also completed the integration of manufacturing, R & D and commercial operation of MSD in China Layout: Hangzhou Xiasha factory, Beijing Asia R & D headquarters and Shanghai commercial operation headquarters The new Hangzhou plant covers a total area of 75000 square meters, and 16 production packaging lines mainly cover the packaging of solid pharmaceutical preparations and sterile drugs in seven major disease fields It is estimated that the annual output will exceed 300 million boxes, so the number of MSD's factories in China has increased to three Not only that, this new factory not only produces new products, but also covers clinical trial drugs and product packaging of commercial projects "Today's new plant is expected to generate an annual output value of 10 billion yuan in 2017, hoping to build into an important pharmaceutical production base in Asia." Tu xingeng, party secretary and director of Hangzhou SASAC, told reporters "On the 22nd anniversary of entering China, MSD's business in China starts from Hangzhou, and Huadong pharmaceutical is the original partner." According to pan bin, President of MSD China However, the way of cooperation is changing subtly Li Bangliang, chairman of East China pharmaceutical, said that in the Hangzhou MSD company established 20 years ago, East China Pharmaceutical Group initially held 25% of the shares, but now the equity has been diluted to 15%, and MSD accounts for the remaining 85% "Last year, the sales volume of MSD and East China pharmaceutical joint venture was 4.3 billion yuan." At present, the production field of MSD covers diabetes, cardiovascular, anti infective drugs and vaccines and other key products "In terms of product introduction, both parties are actively negotiating We are very interested in traditional varieties of MSD, such as cardiovascular products." Li Bangliang pointed out